Prof. Sheng Hu 胡胜
Chief Physician, Professor
Department of Medical Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment for middle and late-stage cancer, with a focus on individualized therapy for lung, intestinal, and brain tumors, as well as targeted therapy.
Dr. Hu holds a PhD from the United States and graduated from Hubei Medical University. With 30 years of clinical experience, Dr. Hu serves as Department Director. In 2009, Dr. Hu visited Ohio State University for pharmaceutical studies. Dr. Hu has led multiple research projects and published over 30 papers.
Professional roles
- Member, Biological Targeted Therapy Professional Committee, China Anti-Cancer Association
- Secretary, Lung Cancer Professional Committee, Hubei Anti-Cancer Association
- Member, Biological Targeted Therapy Professional Committee, Hubei Anti-Cancer Association
- Reviewer, Chinese Journal of Oncology; Journal of Oncology; Journal of Cancer Prevention and Research
Name order: in Chinese the family name comes first (Hu Sheng). Papers usually list the name as Sheng Hu or Hu S.
Selected publications
93 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Commun (Lond), 2026 (senior author): The Five-Decade Journey of Small Cell Lung Cancer. PubMed 42840183
- Drug Resist Updat, 2025 (senior author): Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. PubMed 40081220
- Signal Transduct Target Ther, 2025 (senior author): Advances in molecular pathology and therapy of non-small cell lung cancer. PubMed 40517166
- Front Immunol, 2025 (senior author): A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE(FAP5/CD3), CAR-T cells, and immunotoxins in hepatocellular carcinoma. PubMed 40406146
- J Hepatocell Carcinoma, 2024 (senior author): Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report. PubMed 38854817
- Ann Transl Med, 2022 (senior author): Lung cancer with brain metastases remaining in continuous complete remission due to pembrolizumab and temozolomide: a case report. PubMed 36172106
- Ann Transl Med, 2022 (senior author): A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy. PubMed 35282037
- Front Oncol, 2020 (senior author): Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. PubMed 33014801
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion